# Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma

> **NCT01264341** · PHASE2 · TERMINATED · sponsor: **Hellenic Cooperative Oncology Group** · enrollment: 39 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01264341
- **Lead sponsor:** Hellenic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Based on the developments in the treatment of recurrent metastatic renal cancer, the study treatment is no longer considered to be the best treatment option
- **Last updated:** 2017-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01264341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01264341, "Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01264341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*